李冠乔，副教授、特别研究员。

学科方向：药品评价与监管、药物流行病学、数字健康。

联系方式：guanqiaoli@tsinghua.edu.cn

教育背景：

2008 - 2017   清华大学医学院，临床医学（八年制），医学博士

2008 - 2014   清华大学生命科学学院，生命科学，理学学士

工作履历：

2022 - 至今    清华大学万科公共卫生与健康学院，助理教授、副教授

2019 - 2022   清华大学医学院/清华临床试验中心，助理研究员

2017 - 2019   清华大学医学院/全球健康中心，博士后/助理研究员

2014 - 2017   北京协和医院，临床实习轮转医生

2012 - 2014   美国匹兹堡大学医学院（UPMC）希尔曼癌症中心，访问学者

研究概述：

主要研究方向为药品评价与监管、药物流行病学与数字健康，致力于运用药物流行病学方法，结合数字健康技术与多组学技术，破解医药研发、评价、监管与使用全过程中的重大科学与管理难题，开发新工具和新方法以提升研发效率、完善评价标准、优化监管体系，旨在提升药品的安全性、有效性和可及性，实现保护和促进公众健康。截至目前，研究成果在Nature Reviews Drug Discovery、Nature Reviews Clinical Oncology、Science、Lancet Oncology等期刊发表SCI论文三十余篇，参与撰写多国家级指导原则。主持课题十余项，包括国自然面上一项，入选北京市科技新星计划和北京市青年人才托举工程项目。荣获清华大学青年教师教学大赛一等奖。

重点研究方向包括：1）基于算法的药品有效性和安全性的预测与评价；2）基于多组学和生物信息学的生物标志物开发与潜在靶点发现；3）替代终点、数字化工具等新型研发和监管工具的开发与应用；4）现代化药品科学评价体系建设与监管决策支持；5）真实世界数据驱动的公共健康政策效果评估。

【课题组长期招收博士后和科研助理，欢迎有兴趣的申请者邮件沟通】

代表论文：

新药研发、评价、使用与监管

1. Chen Z, Zhong H, Hu H, Kong F, Liang W#, Li G#. (2024). Chinese innovative drug R&D trends in 2024. Nat Rev Drug Discov. 23: 810-811. (# corresponding authors)

2. Mao X, Alexander C.,Li G#. (2024). Accelerated approvals: early-phase success or premature authorization? Cancer Cell. 11(42):1799-1802. (# corresponding authors)

3. Li X, Zhou Y, Xu B, Qin Y, Zhao J, Li M, Xu J#, Li G#. (2024). Comparison of efficacy discrepancy between early-phase clinical trials and phase III trials of PD-1/PD-L1 inhibitors. J Immunother Cancer. 12(1):e007959.(# corresponding authors)4. Yue J, Liu Y, Zhao M, Bi X, Li G#, Liang W. (2023). The R&D landscape for infectious disease vaccines. Nat Rev Drug Discov. 22(11):867-868.(# corresponding authors)

5. Li G, Liu Y, Ruyi H, Su L, Chen X. (2022) FDA decisions on new oncologic drugs: China’s experience with imported drugs. Lancet Oncology. 23(5):583-585.

6. Li G*, Liu Y*, Hu H, Yuan S, Zhou L, Chen X. (2022) Evolution of innovative drug R&D in China. Nat Rev Drug Discov. 21(8):553-554.

7. Li G, Jiang Y, Qin Y, Yuan S, Chen X. (2022) Comparing development strategies for PD-1/PD-L1-based immunotherapies. Nat Rev Drug Discov. 21(7):484.

8. Liu Y*, Zhang N*, Xie C, Jiang Y, Qin Y, Zhou L, Fan Y, Ren L, Yin C, Yang H, Xie W, Zhai Q, Li G#, Chen H#, Chen X#. (2022) Evolution of drug regulations and regulatory innovation for anticancer drugs in China. Acta Pharmaceutica Sinica B. 12(3):1536-1537.

9. Li G*, Liu Y*, Xie C, Zhou Q, Chen X. (2021) Characteristics of expedited programs on cancer drug approval in China. Nat Rev Drug Discov. 20(6):416.

10. Li G, Qin Y, Xie C, Wu Y, Chen X. (2021) Trends in oncology drug innovation in China. Nat Rev Drug Discov. 20(1): 15-16.

11. Bai X, Jiang S, Zhou Y, Zhen H, Ji J, Li Y, Ruan G, Yang Y, Shen K, Wang L, Li G#, Yang H#. (2021) Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 12:720776. (# corresponding authors)

12. Li G, Liu X, Chen X. (2020) Simultaneous development of zanubrutinib in the USA and China. Nat Rev Clin Oncol. 17(10):589-590.

13. Li G*, Yin C*, Zhou Y, Wang T, Chen J, Liu Y, Chen T, Wang H, Zhang L, Chen X. (2020) Digitalized Adaptation of Oncology Trials during and after COVID-19. Cancer Cell. 38(2):148-149.

公共卫生与药物流行病学

1. Li G, Jiang Y, Zhang L. (2019) HIV upsurge in China's students. Science. 364(6442):711.

2. Li G*, Fan Z*, Zhou Y*, Chen Y*, Shi X, Xie X#, Zhang L#.(2022). The contributions of risk factors on health adjusted life expectancy (HALE) changes from 1990 to 2017: A serial cross-sectional analysis from the GBD study. Global Transitions.4:90–99.

3. Ge C*, Du K*, Luo M, Shen K, Zhou Y, Guo K, Liu Y, Yin C, Li Y, Li G#, Chen X# (2022). Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis. Exp Hematol Oncol. 2022;11(1):46. (# corresponding authors)

4. Li G*, Zhou Y*, Ji J, Liu X, Jin Q, Zhang L. (2021) Surging publications on the COVID-19 pandemic. Clin Microbiol Infec. 27(3):484-486.

5. Lv Y*, Li G*, Hu M*, Xu C*, Lu H*, Xing Y, Liang S, Ma Y, Liang S, Zhuang M, Li Y, Huang C, Bai Y, Jiang Y#, Zhang L#. (2021) Anonymous linkage between college students and facilities: systematic evaluation of urine self-collection for HIV testing initiative in China. Clin Infect Dis. 73(5):e1108-e1115.

6. Chen T*, Huang S*, Li G*, Zhang Y, Zhu J, Shi X, Li X#, Xie G#, Zhang L#. (2021) An integrated framework for modelling quantitative effects of entry restrictions and travel quarantine on importation risk of COVID-19. J Biomed Inform. 118:103800

7. Sun K*, Xu L*, Li G*, Ruan X, Li X, Deng P, Li X, Li Q, Chen X, Xiong Y, Lu S, Qi L, Shen C, Tang W, Rong R, Hong B, Ning Y, Long D, Xu J, Shi X, Yang Z, Zhang Q, Zhuang Z, Zhang L#, Xiao J#, Li Y#. (2019) Forecasting Influenza Activity Using Self-Adaptive AI Model and Multi-Source Data in Chongqing, China. Ebiomedicine. 47:284-292.